164 related articles for article (PubMed ID: 38532079)
1. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
Lechowicz MJ; Smith C; Ristuccia R; Dwyer K
Int J Hematol; 2024 Jun; 119(6):736-744. PubMed ID: 38532079
[TBL] [Abstract][Full Text] [Related]
2. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the risk for graft
Kamada Y; Arima N; Hayashida M; Nakamura D; Yoshimitsu M; Ishitsuka K
Leuk Lymphoma; 2022 Jul; 63(7):1701-1707. PubMed ID: 35225126
[TBL] [Abstract][Full Text] [Related]
8. [Haploidentical transplantation using post-transplant high-dose cyclophosphamide for adult T-cell lymphoma after mogamulizumab treatment].
Kusakabe M; Kurita N; Nishikii H; Sato R; Yoshida C; Yokoyama Y; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2017; 58(5):449-454. PubMed ID: 28592758
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.
Tsubokura Y; Satake A; Hotta M; Yoshimura H; Fujita S; Azuma Y; Nakanishi T; Nakaya A; Ito T; Ishii K; Nomura S
Int J Hematol; 2016 Dec; 104(6):744-748. PubMed ID: 27573760
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
Ishitsuka K; Yasukawa T; Tsuji Y
Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
[TBL] [Abstract][Full Text] [Related]
11. [Adult T cell leukemia-lymphoma with allo-HSCT after treatment for pulmonary involvement with Mogamulizumab].
Kawashima I; Sueki Y; Yamamoto T; Nozaki Y; Nakajima K; Mitsumori T; Kirito K
Rinsho Ketsueki; 2015 Feb; 56(2):210-5. PubMed ID: 25765802
[TBL] [Abstract][Full Text] [Related]
12. [Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma].
Fuji S
Rinsho Ketsueki; 2018; 59(4):426-431. PubMed ID: 29743403
[TBL] [Abstract][Full Text] [Related]
13. [Impact of pretransplant anti-CCR4 antibody administration on clinical outcomes in allogeneic hematopoietic stem cell transplantation].
Fuji S
Rinsho Ketsueki; 2019; 60(8):968-972. PubMed ID: 31484897
[TBL] [Abstract][Full Text] [Related]
14. Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
Weiner DM; Lewis DJ; Spaccarelli NG; Clark RA; Nasta SD; Loren AW; Rook AH; Kim EJ
Dermatol Ther; 2022 Jul; 35(7):e15538. PubMed ID: 35477952
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
[TBL] [Abstract][Full Text] [Related]
17. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
18. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.
Inoue Y; Endo S; Matsuno N; Kikukawa Y; Shichijo T; Koga K; Takaki A; Iwanaga K; Nishimura N; Fuji S; Fukuda T; Nosaka K; Matsuoka M
Bone Marrow Transplant; 2019 Feb; 54(2):338-342. PubMed ID: 30116017
[No Abstract] [Full Text] [Related]
19. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
20. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
